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Abstract: 
Background:The intensive care unit [ICU] is considered as infection epicenter because vulnerable population of critically ill patients and 
use of different invasive devices. Consequently, the ICU population has one of the highest occurrence rates of nosocomial infections leading 
to an enormous impact on morbidity, hospital costs, and often survival. In addition, the increasing problem of antibiotic resistance loads the 
burden of nosocomial infection in the ICU. Constant and careful global monitoring for multidrug-resistant bacteria is needed to minimise 
the possibility of appearance and dissemination of new resistant isolates and to avoid complications in treatment choices. 
Methods:This study was carried out from March to June 2016 in King Khalid Hospital [Al-Kharj-KSA] to explore the multidrug-resistant 
bacteria, Extended Spectrum 𝛽- lactamase bacteria [ESBLs] and the possibility of carbapenems resistant bacteria isolated from clinical 
samples of patients in the ICUs. A total of 317 different clinical samples were received for cultivation and antibiogram during the study 
period. Samples were cultivated on Blood agar, MacConkey agar, CLED, EMB agar and Mannitol salt agar. Gram stain, colony 
morphology and biochemical tests were done.The final identification results of the causative agents and its sensitivity profile were obtained 
by automated procedures "Phoenix 100/BD company". Minimum inhibitory concentration [MIC] results were interpreted according to 
Clinical and laboratory standard institute [CLSI] guidelines. 
Results:Out of 317 total samples processed during the study, significant growth was shown in 62 samples [19.5%]. Respiratory samples 
showed the highest rate of positive growth [40.3% out of 62] followed by urine [20.96% out of 62].  Fifty-seven isolates [91.94 %] were 
gram-negative and five isolates [8.06%] were gram-positive. 
 K. pneumoniae was the most frequently isolated among Gram-negative with16 isolates [28%] followed by P. aeruginosa 12 [21%].  
All isolates of  P. aeruginosa, Acinetobacter spp., Providencia spp., Enterobacter spp., Citrobacter spp., Serratia spp. were MDR [100%] 
while five isolates [71.4%] of Proteus mirabilis, and 11 [69%] of K. pneumoniae were MDR. ESBLs were confirmed in 39 [83%] isolates 
out of 47 MDR gram-negatives; among them, 11[28.2%] were K. pneumoniae and10 [25.64%] isolates of P. aeruginosa. Resistance to 
carbapenems was detected in 23 [48.94%] isolates of MDR gram-negative bacteria; among them, 10 [43.48%] isolates of  P. aeruginosa, 
and 6[26.1%] isolates each of Acinetobacter spp. and K. pneumoniae. 
Conclusion:Considerable efforts and regular evaluation of ESBL and carbapenems resistant bacteria are of great importance both in 
hospital and community to avoid the appearance of new bacterial isolates which may resist all clinically used antibiotics. 
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Nosocomial infection defined as a condition that 
results from an adverse reaction to the presence of 
an infectious agent or its toxins after 48 hours of 
admission to the hospital [1, 2]. It has estimated 
that 90,000 deaths per year worldwide are due to 
nosocomial infection [ 2-5, 24]. In the developed 
countries, it has reported that from 5% to 15% of 
hospitalised patients become infected in regular 
wards and as many as 50% or more of patients in 
intensive care units [ICUs] [6-9].  
Recent treatments command the use of intravenous/ 
urinary catheters, respirators, hemodialysis, 
complicated operations, therapy using cortisone 
and others which depress defence mechanisms and 
make patients susceptible to infections such as 
urinary tract infection, pneumonia, surgical 
infection, catheter infection, bacteremia, and other 
infections [3,12,13,19, 21, 22]. 
 The most common bacteria associated with ICU 
infections are E. coli, Pseudomonas aeruginosa,  
Acinetobacter spp.,  S. aureus,  Klebsiella spp., 
Proteus spp.,  Enterobacter spp., Citrobacter sp. 
and others [10,11,14-17]. 
 The sources of these organisms may be the 
patient's flora, visitors, ICU environments like 
water, air, foods, and equipment, health care 
workers, other patients, or inanimate objects that 
are in close to patients [12,13,18, 20]. 
Bacterial resistance is a serious problem in the 
hospital environment, especially when the infection 
is caused by the multidrug resistance organism 
[23]. Several different mechanisms of bacterial 
drug resistance have been described, for example, 
production of various drug-inactivating enzymes 
like 𝛽- lactamases, multiple efflux pump, and 
reduced uptake [25]. 
 This study was aimed to explore the multidrug-
resistant bacteria, Extended Spectrum 𝛽- lactamase 
bacteria [ESBLs] and the possibility of 
carbapenems resistant bacteria isolated from 
clinical samples of patients in the ICUs [adult, 
pediatric and neonatal ICU ]. 
 
METHODS: 
This study was carried out from March to June 
2016 in King Khalid hospital in Al-Kharj after 
getting ethical approval from King Fahad Medical 
City/Riyadh. IRB No. 16-010E. 
 
Samples 
A total of 317 different samples [Urine, wound, 
Blood, Respiratory, and others] were received by 
Microbiology Lab from ICUs for cultivation and 
antibiogram during the study period [Table 1]. 
There was no direct contact with patients, and there 




Isolation of bacteria 
All clinical specimens received by Microbiology 
lab were treated according to good laboratory 
practice and standard methods for identification. 
Urine and tracheal aspirates, a loop full was 
inoculated onto Blood agar [BA] and MacConkey 
agar [MA], CLED, EMB agar and Mannitol salt 
agar and aerobically incubated at 370 C for 24 
hours. Pus and wound swabs were inoculated onto 
BA, MA, EMB, Chocolate agar [CA] and Mannitol 
salt agar [MSA].  
The BA and CA plates were incubated at370 C for 
24 hours at 5–10% CO2 whereas MA, EMB and 
MSA were incubated aerobically at 370 C for 24 
hours.  
Blood samples were collected in Bactec blood 
culture bottles [BD Blood Culture System, Becton] 
and incubated at 37°C in Bactec 9240 following 
manufacturer instructions. Positive bottles were 
subcultured on BA, CA, MSA, EMB agar and 
MAC agar. 
Gram stain, colony morphology and biochemical 
tests [catalase, oxidase, coagulase] were done for 
initial screening. The final identification results of 
the causative agents were confirmed by automated 
procedures "Phoenix 100/BD company". 
 
Antibiotic susceptibility 
Phoenix 100/BD company machine is used in 
Microbiology lab/ King Khalid hospital for 
identification of bacteria from clinical samples and 
antibiogram. The antibiotics used for testing Gram 
- negative and Gram- positive are shown in Table 
2, and 3, and the minimum inhibitory concentration 
[MIC] results were interpreted according to 
Clinical and laboratory standard institute [CLSI] 
guidelines [26]. 
Multidrug Resistance 
Multidrug-resistant bacteria [MDR] isolates were 
defined when the results show the bacteria as 
resistant to three or more antibiotics belonging to 
different structural classes. 
Extended-spectrum β-lactamase [ ESBLs] gram-
negative bacteria  
ESBLs were defined as the bacteria which 
hydrolyze and cause resistance to β-lactam 
antibiotics including the third generation of 
cephalosporins [Ceftazidime, Ceftriaxone] and 
monobactams [aztreonam] but not carbapenems. 
Resistance to Carbapenems  
The isolates which are ESBLs and show resistance 
to one or more of carbapenems used [Imipenem, 
Meropenem, Ertapenem] were identified as 
possibly carbapenemase producers [51]. 
 
RESULTS: 
Out of 317 total samples processed during the 
study, 60 samples [18.93%] showed significant  
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growth. Respiratory samples 25 [41.66%] were the 
most frequent positive samples followed by urine 
13[21.66%] blood and wound 6 each [10%] and 
other samples including eye swabs, ear swabs and 
umbilical swabs 10 [16.66%] Figure 1&Table 1. 
Out of 60 total isolates, 57 [95%] were Gram- 
negatives, and 3 [5%] were gram-positive. K. 
pneumoniae was the most frequently isolated 
among Gram-negatives with 
16 isolates [26.66%] followed by P. aeruginosa 12 
[20%]. Gram-positive isolates were Staphylococcus 






Fig 1: Right: The bacterial types isolated. Left: Total number of bacteria isolated from clinical sample. 
 
 
Table 1: The number of bacterial types isolated Vs clinical samples. 
 
Bacteria No. of isolates Samples 
Urine Wound Blood Respiratory Others 
E. coli 4[6.66%] 1 1 0 0 2 
K. pneumoniae 16[26.66%] 4 0 3 4 5 
P. aeruginosa 12[20%] 1 0 0 11 0 
Proteus mirabilis 7[11.66%] 1 2 1 3 0 
Acinetobacter 6[10%] 1 1 0 2 2 
Providencia  7[11.66%] 3 2 1 0 1 
Enterobacter  3[5%] 2 0 0 1 0 
Citrobacter  1[1.66%] 0 0 0 1 0 
Serratia  1[1.66%] 0 0 0 1 0 
S. aureus 1[1.66%] 0 0 1 0 0 
MRSA 2[3.33%] 0 0 0 2 0 


























High resistant rates of K. pneumoniae was noticed 
against antibiotics like ampicillin     [100%], each 
of cephalothin, cefuroxime, ceftriaxone [69%], 
ceftazidime and Amox/Calv [62%] and cefepime, 
aztreonam, nitrofurantoin each [56%]. K. 
pneumoniae showed high sensitivity to meropenem 
[100%].  
Similarly, high resistance to each of imipenem, 
meropenem and aztreonam [83%] followed by 
ceftazidime and ciprofloxacin [75%] was found 
against P. aeruginosa but it was highly sensitive to 
each of amikacin and gentamicin [100%]. Detailed 
results are given in Table 2. 
All isolates of  P. aeruginosa, Acinetobacter spp., 
Providencia spp., Enterobacter spp., Citrobacter 
spp., Serratia spp. were MDR [100%] while five 
isolates [71.4%] of Proteus mirabilis, 11 [69%] of 
K. pneumoniae and one isolate [25%] of E. coli 
were MDR. Detailed results are shown in Table 4. 
Among Gram-positive bacteria, Staphylococcus 
aureus [one isolate] and MRSA [2 isolates] were 
identified. Staphylococcus aureus shows high 
sensitivity to mostly all of the antibiotics used 
while both MRSA isolates were MDR but show 
high sensitivity to many antibiotics such as 
vancomycin, nitrofurantoin, daptomycin and 
teicoplanin [100%]. Results are given in Table 
3&4.  
According to the CLSI definition, ESBLs were 
confirmed in 39 [83%] out of 47 MDR gram-
negative isolates. Among them, 11 [28.2%] were K. 
pneumoniae, 10 [25.64%] isolates of P. 
aeruginosa, 7 [17.95%] Providencia spp.,  
Acinetobacter spp. 6 [15.4%], Proteus mirabilis 
3[7.7%] and only one isolate of Serratia spp. and 
E. coli [2.56%]. 
The possibility of resistance to carbapenems was 
observed in 23 [48.94%] isolates of MDR gram-
negative bacteria; among them 10 [43.48%] 
isolates of  P. aeruginosa, 6 [26.1%] each of 
Acinetobacter spp. and K. pneumoniae and one 
isolate only of Serratia spp. Detailed results are 
presented in Figure 2 &Table 4. 
 
Table 2: Gram-negative bacteria and its sensitivity profile with 20 different antibiotics. 
 
Bacteria # AK GN ERT IMI MEM KF CXM FOX CAZ CRO 
E. coli 4 100 100 100 100 100 25 75 100 75 75 
K. pneumoniae 16 81 63 75 88 100 31 31 69 38 31 
P. aeruginosa 12 100 100 0 17 17 0 0 0 25 0 
Proteus mirabilis 7 86 86 71 - 57 43 71 86 71 57 
Acinetobacter 6 0 0 0 - 0 0 0 0 0 0 
Providencia  7 100 0 100 - 100 0 0 100 0 0 
Enterobacter  3 100 100 100 100 100 67 67 67 100 100 
Citrobacter  1 100 100 100 100 100 100 100 100 100 100 
Serratia  1 100 100 0 0 100 0 0 0 100 0 
Cont. 
Bacteria # CPM ATM AMP AUG PRL/TAZ TS NI CIP LEV TIG 
E. coli 4 75 75 25 75 100 0 100 50 50 100 
K. 
pneumoniae 
16 44 44 0 38 63 50 44 50 75 88 
P. aeruginosa 12 25 17 0 0 58 0 0 58 42 - 
P. mirabilis 7 57 57 29 29 100 14 0 57 71 0 
Acinetobacter 6 0 0 0 0 0 67 0 0 0 0 
Providencia  7 0 0 0 0 100 0 0 0 0 0 
Enterobacter  3 100 100 0 67 100 100 100 100 100 67 
Citrobacter  1 100 100 0 100 100 100 100 100 100 100 
Serratia  1 0 100 0 0 100 100 0 100 100 0 
 
AK:Amikacin, GN: Gentamicin, ERT: Ertapenem, IMI: Imipenem, MEM: Meropenem, KF: Cephalothin, 
CXM: Cefuroxime, FOX: Cefoxitin, CAZ: Ceftazidime, CRO: Ceftriaxone, CPM: Cefepime, ATM: Aztreonam, 
AMP: Ampicillin, AUG: Amox/Calv, PRL/TAZ: Piperacillin/Tazobactam, TS: Trimethoprim/Sulfa, NI: 














Table 3: Gram-positive bacteria and its sensitivity profile with 21 different antibiotics. 
 
Bacteria # GN IMI FOX CTX AMP PG OX AUG DAP TS TEIC 
S. aureus 1 100 100 - 100 0 0 100 100 100 100 100 
MRSA 2 50 0 0 0 0 0 0 0 100 100 100 
Enterococcus  2 0 - 0 0 50 0 - - 100 0 100 
 
Bacteria # VAN CD E LIN MU NI CIP MOX RIF TC 
S. aureus 1 100 100 100 100 100 100 100 100 100 100 
MRSA 2 100 100 100 100 100 100 100 100 100 0 
Enterococcus  2 100 0 0 0 - 100 0 0 - 50 
 
GN: Gentamicin, IMI: Imipenem, FOX: Cefoxitin, CTX: Cefotaxime. AMP: Ampicillin, PG: PencillinG.                         
OX: Oxacillin. AUG: Amox/Calv, DAP: Daptomicin. TS: Trimethoprim/Sulfa. TEIC: Teicoplanin.                      
VAN: Vancomycin, CD: Clindamycin. E: Erythromycin. LIN: Linezolid. MU: Mupirocin high level.                    
NI: Nitrofurantoin, CIP: Ciprofloxacin, MOX: Moxifloxacin.RIF: Rifampin.TC: Tetracycline. 
 
Table 4: Multiple drug resistant, ESBLs and carbapenems resistant isolates of gram positive and gram 
negative . 
Bacteria No. of 
isolates 





E. coli 4 1[25%] 1[100%] 0 [0%] 
K. pneumoniae 16 11[69%] 11[100%] 6 [37.5%] 
P. aeruginosa 12 12[100%] 10[83.33%]    10 [83.33%] 
Proteus mirabilis 7 5 [71.4%] 3[60%] 0 [0%] 
Acinetobacter 6 6 [100%] 6[100%]     6 [100%] 
Providencia 7 7[100%] 7[100%] 0 [0%] 
Enterobacter 3 3[100%] 0[0%] 0 [0%] 
Citrobacter 1 1[100%] 0[0%] 0 [0%] 
Serratia 1 1[100%] 1[100%]     1 [100%] 
S. aureus 1 0[0%] - - 
MRSA 2 2[100%] - - 








Fig 2: Multiple drug resistant, ESBLs and carbapenems resistant isolates of  gram negative bacteria. 
 
 









The development of antimicrobial resistance started 
as soon as the antibiotics were used clinically in 
1940. Methicillin-resistant S. aureus [MRSA] had 
been evolved worldwide in 1961which forced the 
use of vancomycin in chronically and severely ill 
patients resulting in the rise of MRSA with reduced 
susceptibility to vancomycin [27-30]. The 
continuing exposure of bacterial strains to some β-
lactams has provoked persistent production and 
mutation of β-lactamases among gram-negative 
bacteria such as E. coli,  Klebsiella pneumoniae,  
Pseudomonas aeruginosa . Such enzymes are 
known as Extended-spectrum β-lactamases 
[ESBLs] which cause resistance to βlactams 
including the third generation of cephalosporins 
[cefotaxime, ceftriaxone, ceftazidime] and 
monobactams [aztreonam] but not carbapenems 
[31,32, 33]. 
In this study low growth rate was found from 
different clinical samples compared with the results 
have been reported in the previous studies carried 
out in ICUs [34,35,36]. The commonest sites of 
infection were respiratory tract infections followed 
by urinary tract and bloodstream infections, and 
gram-negative bacteria such as K. pneumoniae and 
P. aeruginosa were the most prevalent pathogens 
isolated from ICU patients in this study.  
These findings are compatible with other studies 
[36,38,39,41]. However, in other studies, it has 
been shown that Acinetobacter spp. are the major 
nosocomial pathogens of ICU [35,37,40]. This 
difference may be attributed to the difference in 
geographical location, nutritional status, health care 
settings, and immune status of the patient.  
In this study, all isolates of  P. aeruginosa , 
Acinetobacter spp., Providencia spp., Enterobacter 
spp., Citobacter spp., Serratia spp. and isolates of 
Gram-positive were MDR while Proteus mirabilis 
[71.4%] K. pneumoniae [69%] and E. coli [25%] 
were MDR which almost shows similar result 
reported in earlier studies [34,35,42]. 
Out of 39 ESPL isolated, the higher prevalence was 
found in K. pneumoniae 11[28.2%] isolates 
followed by10 [25.64%] isolates of P. aeruginosa, 
7 [17.95%] Providencia spp., and Acinetobacter 
spp. 6 [15.4%].  
A previous study in Nepal reports that a prevalence 
rate of  28.6% of  K. pneumoniae isolates [35, 43] 
and a study in Saudi Arabia conclude that 26% of 
K. pneumoniae were ESBLs [44]. Moreover, data 
over three years investigation in Kuwait showed 
that the levels of ESBLs of K. pneumoniae and E. 
coli isolated from urine samples of inpatient were 
28% and 26%, respectively [45]. A recent study in 
a tertiary hospital in Patiala, Punjab showed that 
ESBL production was confirmed in 50% of P. 
aeruginosa, 48% of E. coli, and 44% of K. 
pneumoniae isolates [46]. A study carried out by 
Majda et al. reported that 72% of E. coli and 65.8% 
of K. pneumoniae isolated from urine samples were 
ESBL producers [47]. In a study done by Shakti et 
al. reported that ESBL positive among ICUs 
isolates was 12.11%, and ESBL positive from 
nosocomial isolates was 22.47% [48]. 
The ESBL rate differs between countries due to the 
difference in the geographical area, the hospital, the 
community, the host and the bacteria and their 
mobile genetic elements.  
Moreover, several risk factors exist for infection 
with ESBL producer like chronic ill patients with 
an extended stay in the hospital, use of invasive 
devices, extensive antibiotic use, recent surgery, 
gastrostomy, and hemodialysis [12, 13, 19, 24]. 
For a long time, carbapenems [imipenem, 
meropenem] are considered as the first choice for 
the treatment of many infections caused by ESBLs 
producing bacteria, but unfortunately 
carbapenemase resistant isolates have been evolved 
in the past years in many countries [10, 49,50, 51]. 
E.G. Playford et al. conclude that 4.6% of patients 
admitted to ICU for more than 48 hours acquired 
carbapenem-resistant Acinetobacter 
baumannii[10]. A study carried out in 7 US 
Communities, Guh AY. et al. reports that the 
overall annual Carbapenem-Resistant 
Enterobacteriaceae incidence rate per 100000 
population was 2.93 which were isolated mostly 
from urine and blood [51]. In this study, 23 
[48.94%] out of 47 MDR gram-negative isolates in 
which all  Acinetobacter spp. 6 [100%] isolates, P. 
aeruginosa 10 [83.33%] isolates and K. 




The frequency of infections caused by ESBL and 
carbapenems resistant bacteria has increased in 
recent years. Detection of ESBL and MDR 
carbapenems is of great importance both in hospital 
and community. The prevalence and incidence of 
these bacteria are becoming more complicated with 
increasingly fuzzy borders between community and 
hospitals.  
 Probably, a ‘‘super germ’’, resistant to relatively 
all clinically used antibiotics, is expected in the 
future. Constant and careful worldwide monitoring 
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